BioLine RX Ltd (NASDAQ:BLRX)
| 2.52 Delayed Data As of Jan 22 |  -0.01 / -0.40%Today’s Change | 1.06 Today|||52-Week Range 3.72 | 0.00% Year-to-Date |
Latest BLRX News | Press Releases
| Aclaris (ACRS) Up on Preliminary Data for MK2 Inhibitor in RA Jan 20 / Zacks.com - Paid Partner Content |
Today’s Trading
| Previous close | 2.53 |
| Today’s open | 2.47 |
| Day’s range | 2.44 - 2.56 |
| Volume | 58,715 |
| Average volume (3 months) | 4,319,937 |
| Market cap | $66.0M |
Data as of 4:23pm ET, 01/22/2021
Growth & Valuation
| Earnings growth (last year) | +17.27% |
| Earnings growth (this year) | +53.49% |
| Earnings growth (next 5 years) | -25.00% |
| Revenue growth (last year) | -- |
| P/E ratio | NM |
| Price/Sales | -- |
| Price/Book | 0.95 |
Competitors
| Today’s change | Today’s % change | |
|---|---|---|
| SVRASavara Inc | +0.01 | +0.56% |
| MRKRMarker Therapeutics ... | +0.03 | +1.48% |
| --Ecogreen Internation... | -0.00 | -0.78% |
| QLGNQualigen Therapeutic... | +0.01 | +0.29% |
Data as of 3:59pm ET, 01/22/2021
Financials
| Next reporting date | March 10, 2021 |
| EPS forecast (this quarter) | -$0.24 |
| Annual revenue (last year) | $0.00 |
| Annual profit (last year) | -$25.5M |
| Net profit margin | -- |
Profile
Sector Health Technology |
Industry Pharmaceuticals: Other |
No executives to display |
Corporate headquarters Modi'in, Hamerkaz |
Forecasts
